Author

G. Bryson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

D. Ennis· 2 shared A. Biankin· 1 shared A. Clamp· 1 shared A. DeFazio· 1 shared A. Hanif· 1 shared A. Hoyle· 1 shared A. M. Piskorz· 1 shared A. Montes· 1 shared

Activity by Year

2017-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Ennis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

Copy-number signatures and mutational processes in ovarian carcinoma

G. Macintyre, T. Goranova, D. De Silva, D. Ennis, A. M. Piskorz, M. Eldridge, D. Sie, L.-A. Lewsley, A. Hanif, C. Wilson, S. Dowson, R. M. Glasspool, M. Lockley, E. Brockbank, A. Montes, , J. D. Brenton

This study identifies copy-number signatures in ovarian cancer and links them to mutational processes, showing that most cases involve multiple processes, suggesting therapeutic challenges.

bioRxiv · Sep 4, 2017Cancer Biology